All posts by: Cameron Institute

Continence Home Care

Fecal incontinence is an embarrassing and debilitating condition that has become a major, growing health concern and remains grossly understudied. In the Journal of Health Science we have identified the need for on-going education and training of both paid and volunteer care-givers; the proper listing of FI as a subsidizable disability that impairs quality-of-life; and

Be Wary of Canada’s Drug Price Controls and Lack of Intellectual Property Protections

In their March 19, 2018 article in The Hill, Bob Freeman and Wayne Taylor warn the United States about Canada’s drug price controls and lack of intellectual property protection. A copy of that article is attached in the link below. The Hill March 19, 2018  

Access to Needed Medicine

The opinion piece, found in the link below was p,ublished on March 10, 2018 in The Record and on March 11, 2018 in The Hamilton Spectator. Wayne Taylor shows why proposed changes to the Patented Medicine Prices Review Board will further deny Canadians access to needed medicines. Canadian Access to Medicines

Alberta Needs a Coherent Pharmaceutical Policy

In his opinion piece, published on March 15, 2018 in The Edmonton Journal and appearing in the link below, John Bachynsky calls for comprehensive drug coverage in Alberta. The Edmonton Journal March 15, 2018

Continence Training Needs Assessment of Homecare Personal Support Workers and Family Carers

The summative report prepared by Jacqueline Cahill and Dr. D. Wayne Taylor illustrates that fecal incontinence (FI) is an embarrassing and debilitating condition that is becoming a major, growing health concern for men and women of all ages worldwide. Recent research shows that professional caregivers, as well as family carers, in providing FI care in

What’s Wrong With Canadian Healthcare

“What’s Wrong With Canadian Healthcare?” shows that Bismarckian healthcare systems, in which there is market competition amongst insuring entities (no/low wait times, access to novel drugs, and low costs) outperform Beveridge systems that have state monopolies in financing (wait times, limited drug access, and higher costs). For Canada, with its Beveridge system, this means that Canadian healthcare

Drug Benefit Program Myths

Public drug programs have a rather bizarre context. Government announcements appear to be based on the assumptions that drug prices are too high, pharmaceutical firms profits are excessive, new products usually represent minor improve at inappropriately high prices, and that there are other therapies that provide equally effective care at a lower cost. Based on

Canada’s Protection of Intellectual Property

One of the major reasons Canada has so few high-value add manufacturing jobs and high-value add science-based research and development jobs is that Canada’s Intellectual Property (IP) protection regime is out-of-step with that of its by-far largest, and most important trading partner and investor, the United States. If Canada is serious about creating high-value add

20 Myths About Drug Benefit Programs

Dr. John Bachynsky, Patient Advocate for The Cameron Institute, outlines his twenty drug benefit program myths. Drug Benefit Program Myths

Review of Pan-Canadian Health Organizations

In the fall of 2018, Health Canada commissioned a review of the Pan-Canadian Health Organizations. The submission posted below represents the view of the Executive Director of The Cameron Institute and not those of the Board or The Institute. Dr. Taylor purports that with the exception of the Canadian Institute for Health Information, in its collection and dissemination